The prevalence and cost of type-2-diabetes mellitus (T2DM) are escalating globally. The comorbidities between T2DM, depression and anxiety are common. Achieving high adherence to therapy, supported by lifestyle adjustment is the gold standard for good diabetes management. This study aimed to explore the impact of mental ill-health on medication adherence behaviors in patients diagnosed with T2DM. Participants were recruited from a single general medical practice in Birmingham, and randomly allocated into group A and group B. All participants had their HbA1c and blood pressure (BP) measured, their medication adherence, depression, and anxiety screened at each consultation. Of 64 patients, those with secondary school education, physically active, unemployed, did not have online access to resources, were mentally healthy and from Pakistani ethnicity, had better diabetes medications adherence. Regression analysis showed a significant statistical difference (p<0.05) in the unintentional diabetes medication adherence and anxiety scores favoring group A. BP showed a significant difference between baseline and endpoint but no difference was observed between groups. The use of Morisky® software has allowed the screening of the underlying cause of medication adherence, depression, and anxiety promptly. The study identified the importance of medication adherence in diabetes and the impact this has on HbA1c and mental health. The study also proposed two algorithms, one for T2DM patients in general and one for patients from the Muslim faith, and showed how clinicians can adapt their consultations to meet the needs of an individual.
1. Ahmed IA, Alosaimi ME, Alkhathami SM, Alkhurayb NT, Alrasheed MS, Alanazi ZM, et al. Knowledge, attitude, and practices towards diabetes mellitus among non-diabetes community members of Riyadh, Kingdom of Saudi Arabia. Int J Pharm Res Allied Sci. 2020;9(1):41-51.
2. Adiga U, Kathyayani P. Association of Insulin Resistance with Liver Biomarkers in Type 2 Diabetes Mellitus. Int J Pharm Phytopharmacol Res. 2019;9(1):88-91.
3. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric A, American Psychiatric Association, Arlington, VA: American Psychiatric Association; 2013.
4. Graham E, Deschênes SS, Rosella LC, Schmitz N. Measures of depression and incident type 2 diabetes in a community sample. Ann Epidemiol. 2021;55:4-9. doi:10.1016/j.annepidem.2020.11.010
5. Aroke D, Mapoure YN, Mbarga TNF, Dimala CA, Danwe VK, Njamnshi AK, et al. Prevalence and factors associated with depression among type 2 diabetes patients in a Reference Hospital in Cameroon. Neurol Psychiatry Brain Res. 2020;37:123-8. doi:10.1016/j.npbr.2020.08.005
6. Bashir T, Morrissey H, Ball P. Systematic review of psychological and educational interventions used to improving adherence in diabetes and depression patients. Arch Pharm Pract. 2021;12(3):1-11. doi:10.51847/q8elnfrbh6
7. Chepulis L, Morison B, Lao C, Keenan R, Paul R, Lawrenson R. The prevalence of mental health medication use in a cohort of New Zealand patients with diabetes. Prim Care Diabetes. 2020;14(6):703-8. doi:10.1016/j.pcd.2020.07.004
8. Kumar A, Gupta R, Thomas A, Ajilore O, Hellemann G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch Gen Psychiatry. 2009;66(3):324-30. doi:10.1001/archgenpsychiatry.2008.548
9. Ryan JP, Sheu LK, Critchley HD, Gianaros PJ. A neural circuitry linking insulin resistance to depressed mood. Psychosom Med. 2012;74(5):476-82. doi:10.1097/PSY.0b013e31824d0865
10. Pouwer F, Kupper N, Adriaanse MC. Does emotional stress cause type 2 diabetes mellitus? A review from the European Depression in Diabetes (EDID) Research Consortium. Discov Med. 2010;9(45):112-8.
11. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54. doi:10.1111/j.1751-7176.2008.07572.x
12. Zimmerman M, Chelminski I, McGlinchey JB, Posternak MA. A clinically useful depression outcome scale. Compr Psychiatry. 2008;49(2):131-40. doi:10.1016/j.comppsych.2007.10.006
13. Zimmerman M, Kiefer R, Kerr S, Balling C. Reliability and validity of a self-report scale for daily assessments of the severity of anxiety symptoms. Compr Psychiatry. 2019;90:37-42. doi:10.1016/j.comppsych.2018.12.014
14. Zimmerman M, McGlinchey JB. Depressed patients' acceptability of the use of self-administered scales to measure outcome in clinical practice. Ann Clin Psychiatry. 2008;20(3):125-9. doi:10.1080/10401230802177680
15. Zimmerman M, Posternak MA, McGlinchey J, Friedman M, Attiullah N, Boerescu D. Validity of a self-report depression symptom scale for identifying remission in depressed outpatients. Compr Psychiatry. 2006;47(3):185-8. doi:10.1016/j.comppsych.2005.07.004
16. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101. doi:10.1191/1478088706qp063oa
17. NICE Guideline NG28, Type 2 diabetes in adults: management: National Institute for Health and Care Excellence; 2015. Available from: https://www.nice.org.uk/guidance/ng28. Access Date 27/20/2021
18. Bibi N, Wara B, Mughal S, Morrissey H, Ball P. A critical literature review and audit of real-world data to inform the relationship between mental ill-health and type-2 diabetes favorable prognosis. Int J Pharm Pharm Sci. 2020;12(2):43-7. doi:10.22159/ijpps.2020v12i2.36393
Copyright © 2024 - All Rights Reserved - Archives of Pharmacy Practice
Developed by Archives of Pharmacy Practice
